Therapeutics Acquisition Corp. (RACA)
|Net Income (ttm)||n/a|
|Trading Day||April 16|
|Day's Range||9.98 - 10.10|
|52-Week Range||9.91 - 21.44|
Australis Capital completes first phase of Green Therapeutics acquisition with cannabis subsidiary purchase
Australis Capital Inc (CSE:AUSA) (OTC:AUSAF) (FRA:AC4) announced Wednesday that it has completed the first stage of its previously announced acquisition of Nevada cannabis company Green Therapeutics LLC...
Takeda Pharmaceutical Co Ltd (NYSE: TAK) has exercised the option to acquire Maverick Therapeutics, following an agreement signed in 2017, in which Takeda received an equity stake and an exclusive right...
These shell companies allow the businesses they acquire to go public much more quickly than an IPO would. Is it time to buy in?
BOSTON--(BUSINESS WIRE)--Therapeutics Acquisition Corp. (Nasdaq: TXAC) (the u201cCompanyu201d) announced today that on July 10, 2020 it closed its initial public offering of 13,570,000 shares of Class A...
The special purpose acquisition company is sponsored by RA Capital Management.
Therapeutics Acquisition Corp., doing business as Research Alliance Corp. I, does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the healthcare industry in the United States. The company was incorporated in 2020 and is based in Boston, Massachusetts.
|IPO Date |
Jul 8, 2020
|Stock Exchange |
|Ticker Symbol |